Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/11/2017
SIETES contiene 92128 citas

 
 
 1 a 20 de 37 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Prasad V, Mailan S. Research and development spending to bring a single cancer drug to market and revenues after approval. JAMA Intern Med 2017;177:1569-75. [Ref.ID 102051]
2.Enlace a cita original Cita con resumen
Castañeda-Sanabria J, Hjage D, Le Jouan M, Perozziello A, Tubach F. Off-label use of the expensive orphan drug eculizumab in France 2009-2013 and the impact of literature: focus on the transplantation field. Eur J Clin Pharmacol 2016;72:737-46. [Ref.ID 100370]
3. Cita con resumen
Kelly RJ, Höchsmann B, Szer J, Kulasekararaj A, de Guibert S, Röth A, Weitz IC, Armstrong E, Risitano AM, Patriquin CJ, Terriou L, Muus P, Hill A, Turner MP, Schrezenmeier H, Peffault de Latour R. Eculizumab in pregnant patients with paroxysmal nocturnal hemoglobinuria. N Engl J Med 2015;373:1032-9. [Ref.ID 99533]
4. Cita con resumen
Anónimo. Éculizumab et hémoglobinurie paroxystique nocturne chez les enfants. Prescrire 2015;35:11. [Ref.ID 98899]
6.Tiene citas relacionadas Cita con resumen
Legendre CM, Licht C, Loirat C. Eculizumab in atypical hemolytic-uremic syndrome. The authors reply. N Engl J Med 2013;369:1379-80. [Ref.ID 96341]
7.Tiene citas relacionadas Cita con resumen
Tanimoto T, Oshima Y, Kami M. Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;369:1378-9. [Ref.ID 96340]
8.Tiene citas relacionadas Cita con resumen
Kistler AD. Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;369:1378. [Ref.ID 96339]
9.Tiene citas relacionadas Cita con resumen
Amadio A, Tejani AM. Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;369:1378. [Ref.ID 96338]
10.Tiene citas relacionadas Cita con resumen
Ring T. Eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med 2013;369:1377-8. [Ref.ID 96337]
11.Tiene citas relacionadas
Legendre CM, Licht C, Muus P, Greenbaum S, Babu C, Bedrosian C, Bigham DJ, Cohen Y, Delmas K, Douglas F, Eitner F, Feldkramp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nümberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhack LB, Goodship T, Loirat C. Terminal complement inhibitor eculizumab in atypical hemolytic - Uremic syndrome. N Engl J Med 2013;368:2169-81. [Ref.ID 95603]
13. Cita con resumen
Yuki N, Hartung H-P. Medical progress: Guillain-Barré syndrome. N Engl J Med 2012;366:2294-304. [Ref.ID 93212]
14. Cita con resumen
Stevens AJ, Jensen JJ, Wyller K, Kilgore PC, Chatterjee S, Rohrbaugh ML. The role of public-sector research in the discovery of drugs and vaccines. N Engl J Med 2011;364:535-41. [Ref.ID 90172]
15.
Risitano AM, Notaro R, Luzzatto L, Hill A, Kelly R, Hillmen P. Paroxysmal nocturnal hemoglobinuria - Hemolysis before and after eculizumab. N Engl J Med 2010;363:2270-2. [Ref.ID 89757]
16. Cita con resumen
Berzuini A, Montanelli F, Prati D. Hemolytic anemia after eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med 2010;363:993-4. [Ref.ID 89305]
17.
Zimmerhackl LB, Hofer J, Cortina G, Würzner R, Khursigara G, Kliche K-O, Radauer W. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 2010;362:1746-8. [Ref.ID 88477]
18.
Lonze BE, Singer AL, Montgomery RA. Eculizumab and renal transplantation in a patient with CAPS. N Engl J Med 2010;362:1744-5. [Ref.ID 88476]
19. Cita con resumen
Giezen TJ, Mantel-Teeuwisse M, Straus SMJM, Egberts TCG, Balckburn S, Persson I, Leufkens HGM. Evaluation of post-authorization safety studies in the first cohort of EU risk management plans at time of regulatory approval. Drug Saf 2009;32:1175-87. [Ref.ID 87302]
20.Enlace a cita original
Dubois EA, Cohen AF. Eculizumab. Br J Clin Pharmacol 2009;68:318-9. [Ref.ID 86707]
Seleccionar todas
 
 1 a 20 de 37 siguiente >>